Whether progress will be made on the discussions on extending reimbursement of the multiple myeloma treatment ‘Darzalex’ as second-line treatment is gaining attention.

According to industry sources, Janssen Korea is reattempting to apply for reimbursement of its 'Darzalex (daratumumab)' to be reviewed by the Health Insurance Review and Assessment Service's Cancer Disease Deliberation Committee.

The company had succeeded in setting reimbursement standards for Dazarlex as first-line therapy for multiple myeloma in combination with Velcade® + thalidomide + dexamethasone (DVTd), and the agenda is awaiting deliberation by the Drug Reimbursement Review Committee (DREC) soon.